AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03162575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
Study NCT04436068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperfine MRI scan
Description: Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.
Study NCT03640650 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dropless Therapy
Description: The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
Study NCT03640650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
Study NCT02703922 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: color Doppler ultrasound and TAB in case of CDU negative
Description: Screening with color Doppler ultrasound followed by TAB in case of CDU negative
Study NCT00818116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR Aspheric IOL
Description: Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
Study NCT04255628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET
Description: Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
Study NCT04835155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Premature Infant Oral Motor Intervention (PIOMI)
Description: The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
Study NCT02549469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAY117031), 20% HPMC
Description: 1 tablet 660 mg administered orally once daily
Study NCT02549469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAY117031), 30% HPMC
Description: 1 tablet 660 mg administered orally once daily
Study NCT02549469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAY117031), 40% HPMC
Description: 1 tablet 660 mg administered orally once daily
Study NCT03511352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand More
Description: Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Study NCT02549469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aleve (Naproxen Sodium, BAY117031)
Description: 1 tablet 220 mg administered orally three times daily
Study NCT00810264 — intervention group
Intervention type: DEVICE
Intervention: CRT Therapy - LV Lead Registry
Description: Collecting long-term safety and efficacy data on a market-released left ventricular lead.
Study NCT05873608 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational video
Description: Testing an educational video
Study NCT05873608 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Participate in interview
Study NCT05873608 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Undergo observation
Study NCT04197843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviCam (ANKON)
Description: The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
Study NCT01159054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Nicotinic Acid (Niaspan)
Description: Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
Study NCT00575926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LingZhi capsule
Description: LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
Study NCT00575926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LingZhi capsule
Description: LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
Study NCT01527734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin
Description: 15ug and 30ug once or twice a day for 1 or 2 days.
Study NCT01527734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1ml once or twice a day for 1 or 2 days.
Study NCT03156660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight gain prevention (Group 1)
Description: Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~1. Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~2. Daily self-monitoring of steps and number of Small Changes~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Fit Bit Alta activity trackers to self-monitor steps
Study NCT03156660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (Group 2)
Description: Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~1. Tailored calorie and fat goals based on their baseline weight.~2. Daily dietary intake and physical activity self-monitoring using a website or app.~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~5. Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~6. Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~7. Fit Bit Alta activity trackers to self-monitor steps
Study NCT03156660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided intervention (Group 3)
Description: Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~1. EatingWell Diet book.~2. Daily weight self-monitoring on the BodyTraceTM e-scale
Study NCT00500903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
Study NCT02452723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISC-hpNSC
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1120
Description: TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig 2100 mg
Description: Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg
Description: Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig 600 mg
Description: Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig 1200 mg
Description: Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG126
Description: ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO-108 1800 mg
Description: IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
Study NCT03167099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full Weight Bearing
Description: full weight bearing after fixation of a distal femur fracture
Study NCT02468557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily
Study NCT02468557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
Study NCT02468557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
Study NCT03602014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Northera
Description: Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
Study NCT03602014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Northera
Description: Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
Study NCT03602014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
Study NCT00843453 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood collection
Description: blood collection
Study NCT00843453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment (cyanocobalamin nasal spray)
Description: cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
Study NCT00631176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-In-Time Training
Description: On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
Study NCT01533428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8%
Description: Capsaicin 8% transdermal delivery system
Study NCT01533428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Patch
Study NCT05979181 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean hysterectomy
Description: Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)
Study NCT03055533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headsprout reading program
Description: Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
Study NCT00418483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 25 mg
Description: Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
Study NCT00418483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 50 mg
Description: Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
Study NCT00418483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 75 mg
Description: Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
Study NCT00418483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 100 mg
Description: Plasmin (Human) 100 mg
Study NCT00418483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 125 mg
Description: Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
Study NCT00418483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 150 mg
Description: Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
Study NCT00418483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin (Human) 175 mg
Description: Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
Study NCT03994445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone-Based Intervention
Description: We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives .
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKT2152
Description: NKT2152 will be administered by mouth.
Study NCT04524871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO-108 1200 mg
Description: IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
Study NCT03306212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Study NCT03306212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Study NCT03306212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Study NCT03306212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Study NCT03306212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent serial casting
Study NCT01311674 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine
Description: Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL
Study NCT01311674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
Study NCT02917707 — intervention group
Intervention type: OTHER
Intervention: normal colorectal tissues
Description: The investigators will extract total protein, DNA and RNA from these groups.
Study NCT03283904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention
Description: School-based multicomponent intervention
Study NCT01188434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITSAN
Description: integrated behavioral intervention for substance abuse, parenting skills, and basic needs
Study NCT01188434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Services as usual referred by child welfare
Study NCT03580733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin antifungal therapy
Description: caspofungin
Study NCT03580733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01657058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble viscous fibre blend powder in hydrophobic matrix
Description: 5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
Study NCT01657058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble viscous fibre blend in pre hydrated form
Description: 0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
Study NCT01657058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No soluble viscous fibre blend
Description: 0g soluble viscous fibre blend margarine + white bread + jello
Study NCT01657058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble viscous fibre blend premixed with ½ carbohydrate gel
Description: Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
Study NCT01657058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No soluble viscous fibre blend, ½ carbohydrate jello
Description: Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
Study NCT04642508 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prepectoral reconstruction
Description: Immediate prepectoral breast reconstruction in women requiring a mastectomy
Study NCT03538470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Treatment
Description: * Bath with immersion shower~* Overall penetrating shower~* Multiple local application cataplasm~* Individual physiotherapy~* Mobilisation pool
Study NCT03520764 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New infant formula with synbiotics
Description: Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
Study NCT03520764 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula with prebiotics
Description: Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
Study NCT00344461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine, FTC, and Tenofovir
Description: One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
Study NCT02069444 — intervention group
Intervention type: PROCEDURE
Intervention: Macintosh laryngoscope
Description: intubation criterias withMacintosh laryngoscopein pediatric patients
Study NCT02069444 — intervention group
Intervention type: PROCEDURE
Intervention: Truview EVO2 laryngoscope
Description: intubation criterias with Truview EVO2 laryngoscope in pediatric patients